Editas Medicine vs Intellia Therapeutics
EDIT and NTLA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EDIT and NTLA compare
Intellia Therapeutics is the larger company, worth 4.4 times as much as Editas Medicine ($1.6B against $366M).
Editas Medicine grew revenue faster over the last twelve months (7.4% versus −8.1% for Intellia Therapeutics).
Editas Medicine keeps more of each dollar of sales as profit, with a net margin of −145% compared with −806% at Intellia Therapeutics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EDIT | NTLA |
|---|---|---|
| Size and price | ||
| Market cap | $366M | $1.6B |
| Share price | $2.38 | $11.41 |
| Change, 1 year | −5.6% | 17.3% |
| Change, 5 years | −93.3% | −91.2% |
| Beta (5Y) | 2.19 | 2.11 |
| Employees | 87 | 377 |
| StockData Score | ||
| Total score | 3 | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 | 1 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.3× (better) | 30.2× |
| P/B | 4.3× | 2.6× (better) |
| FCF yield | −30.2% | −22.4% (better) |
| Fair value | $1.62 | $7.99 |
| Margin of safety | −47.2% | −42.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 7.4% (better) | −8.1% |
| Revenue growth, 5Y average | −14.9% | 3.1% (better) |
| Profitability | ||
| Operating margin | −152% (better) | −821% |
| Net margin | −145% (better) | −806% |
| FCF margin | −222% (better) | −677% |
| Return on equity | −147% | −62.6% (better) |
| Return on invested capital | – | −152% |
| Financial health | ||
| Debt / equity | 0.67 | 0.12 (better) |
| Interest coverage | −10.6× | – |
| Current ratio | 2.82 | 6.31 (better) |
| Altman Z-score | −9.39 | −2.18 (better) |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | −36.6% | – |
| Shareholder yield | −36.6% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 78.3% | 103% |
| Held by insiders | 0.45% | 2.0% |
| Insider net buying, 12 months | −$107K (better) | −$869K |
| Short interest, % of float | 25.3% | 32.3% |
Go deeper
- EDIT stock overview
- EDIT income statement
- EDIT valuation and score
- NTLA stock overview
- NTLA income statement
- NTLA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.